New York State Common Retirement Fund Grows Stock Position in Evolent Health, Inc. (NYSE:EVH)

New York State Common Retirement Fund raised its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,472 shares of the technology company’s stock after acquiring an additional 6,564 shares during the quarter. New York State Common Retirement Fund owned approximately 0.09% of Evolent Health worth $3,352,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EVH. Cetera Trust Company N.A purchased a new position in shares of Evolent Health during the 4th quarter worth approximately $303,000. Handelsbanken Fonder AB increased its position in Evolent Health by 22.1% during the fourth quarter. Handelsbanken Fonder AB now owns 18,200 shares of the technology company’s stock worth $601,000 after buying an additional 3,300 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Evolent Health by 1,470.7% in the fourth quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock worth $48,000 after acquiring an additional 1,353 shares during the last quarter. Xponance Inc. purchased a new stake in shares of Evolent Health in the fourth quarter valued at $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Evolent Health by 12.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,355 shares of the technology company’s stock valued at $771,000 after acquiring an additional 2,677 shares during the last quarter.

Analyst Ratings Changes

Several brokerages recently weighed in on EVH. JMP Securities boosted their target price on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research note on Friday, February 23rd. JPMorgan Chase & Co. reduced their price objective on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, March 15th. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th. Citigroup assumed coverage on Evolent Health in a report on Monday, April 22nd. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Oppenheimer assumed coverage on Evolent Health in a research note on Friday, March 1st. They issued an “outperform” rating and a $45.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

Evolent Health Stock Down 1.1 %

EVH opened at $27.10 on Monday. Evolent Health, Inc. has a 1 year low of $23.33 and a 1 year high of $35.83. The firm has a 50 day moving average price of $31.41 and a 200 day moving average price of $30.28. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.01. The company has a market cap of $3.13 billion, a PE ratio of -21.34 and a beta of 1.57.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.13. The company had revenue of $556.06 million during the quarter, compared to analyst estimates of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. Sell-side analysts expect that Evolent Health, Inc. will post 0.87 earnings per share for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.